Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose cohorts in Q1 2022 and initial efficacy results in mid-2022…
>> CLICK HERE << Get A FREE Copy Of My Special Report
“Can Your Retirement Survive” Today!
We Even Pay For Shipping & Handling!
|Click Here To Request Your FREE IRS Loophole Guide
This post contains affiliate links. If you use these links to buy something we may earn a commission. Thanks.”